Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06248528 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06248528 · ClinicalTrials.gov record · last posted 2025-07-16

Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.

StatusActive, Not Recruiting
PhaseNot applicable
Started2019-12-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C. For the treatment of PVTT, there are differences between Eastern and Western guidelines, with systemic drugs being the standard of care in Western countries, while surgical treatment is often actively practiced in the Asia-Pacific region. More research is needed to explore the differences between these two approaches.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-01-31; most recent amendment 2025-07-11. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-07-11
Status change Recruiting→Active, Not Recruitingv2
Trial Details
NCT Number NCT06248528
Lead Sponsor Chen Xiaoping
Conditions Hepatocellular Carcinoma
Enrollment 1,076 participants
Start Date 2019-12-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-16